Do patients with cholangiocarcinoma need genetic testing when using pemetinib, and what is the medication method?

Pemetinib (Pemetinib) is a small molecule kinase inhibitor drug developed by Incyte Biopharmaceutical Company in the United States. It is mainly used to treat locally advanced or metastatic cholangiocarcinoma. It is the world's first targeted drug for cholangiocarcinoma. It achieves therapeutic effects by precisely inhibiting the activity of fibroblast growth factor receptors (FGFR) 1, 2, 3 and 4, blocking cancer cell reproduction signals. The emergence of pemetinib provides a new treatment option for patients with cholangiocarcinoma. Its unique targeting mechanism and low side effects allow patients to maintain a better quality of life during treatment.

As to the question of whether genetic testing is required for patients with cholangiocarcinoma taking pemetinib, the answer is yes. Pemetinib is mainly suitable for patients with cholangiocarcinoma with FGFR2 gene fusion or rearrangement. FGFR gene fusion/rearrangement, translocation and amplification are likely to lead to the occurrence of various cancers, including cholangiocarcinoma. Therefore, before using pemetinib, patients need to confirm whether there is FGFR2 gene fusion or rearrangement through genetic testing. This step is critical to ensure the effectiveness and safety of the drug.

Regarding the use of pemetinib, patients need to follow the doctor’s advice and the guidance in the drug package insert. The recommended dose of pemetinib is 13.5 mg orally daily for 14 days, followed by 7 days off in a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Patients should swallow the tablets whole and do not chew or crush the tablets to take with or without food. Depending on the patient's physical condition and tolerance to the drug, the doctor may adjust the dosage.

While taking pemetinib, patients should pay close attention to changes in their physical condition and promptly report any discomfort or abnormal reactions to their doctor. Pemetinib may cause some side effects, including diarrhea, nausea, taste change, vomiting, loss of appetite, weight loss, constipation, joint pain, painful urination, swelling and pain in limbs or joints, blurred vision, etc. If serious side effects occur, patients should seek medical treatment promptly and have a professional doctor adjust the treatment plan.

In summary, patients with cholangiocarcinoma need to undergo genetic testing to confirm the presence of FGFR2 gene fusion or rearrangement before using pemetinib. At the same time, they should follow the doctor's advice and the instructions on the drug package insert to ensure the effectiveness and safety of the treatment.